Raymond James Upgrades Korro Bio to Outperform, Turns Bullish on Hyperammonemia Pivot

Raymond James upgrades Korro Bio to Outperform from Market Perform with $23 PT, bullish on pivot to hyperammonemia programs in UCDs & HE with strong preclinical data and high unmet need.